Reach Us +1-217-403-9671
Novel Approaches Of Bioavailability And Bioequivalence Studies | 8236
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Novel approaches of bioavailability and bioequivalence studies

2nd World Congress on Bioavailability & Bioequivalence: Pharmaceutical R & D Summit-2011 and International Conference on Pharmaceutics & Novel Drug Delivery Systems

Barbara M. Davit

ScientificTracks Abstracts: JBB

DOI: 10.4172/2153-2435.10000S4

T he US-FDA?s regulations defi ne bioequivalence as the lack of a signifi cant diff erence in the rate and extent to which a drug becomes available at the site of action when administered at the same dose under similar conditions in an appropriately designed study. For systemically active drugs, bioequivalence between a test and reference product is generally determined in an in vivo bioequivalence study in which drug rate and extent of absorption are determined from plasma pharmacokinetic profi les. However, bioequivalence evaluation is more challenging for drug products intended for local activity, such as drugs to treat diseases of the gastrointestinal (GI) tract. Th is presentation will address the use of studies with pharmacodynamic, clinical, and / or in vitro endpoints to determine bioequivalence of locally-acting GI drug products. Several case studies will be presented to illustrate the application of these various novel bioequivalence approaches
Dr. Barbara Davit completed her Ph.D from the University of California, Davis, and postdoctoral studies from the California Primate Research Center. Dr. Davit also holds a law degree from George Mason University School of Law. Dr. Davit is currently the Acting Director of the Division of Bioequivalence 2 in the Of fi ce of Generic Drugs, CDER, US-FDA. Her Division of 40 scientists reviews bioequivalence studies for generic versions of neuropharmacological drugs, antiviral and antibiotic drugs, cardiovascular drugs, analgesics, and locally-acting drugs to treat GI diseases. She has published over 25 peer-reviewed articles and given over 100 invited presentations.